Today In History
Chester Stone patented a washing machine.
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 7425437 | Vaccines against West Nile Virus The present invention relates to novel vaccines containing (whole-inactivated) West Nile Viruses and/or West Nile viral proteins derived therefrom, produced on human cells, wherein the human cells comprise a sequence encoding at least one early region-1 (E1) gene pr... | 09/16/2008 |
| 7413889 | Production of a parvovirus vaccine in plants as viral coat protein fusions The present invention relates to foreign peptide sequences fused to recombinant plant viral structural proteins and a method of their production. Fusion proteins are economically synthesized in plants at high levels by biologically contained tobamoviruses. The fusio... | 08/19/2008 |
| 7354190 | Two-stage mixing system, apparatus, and method A two-stage mixing system, apparatus, and method produces a solution including a first substance and a second substance in a predetermined ratio by first mixing the first substance with a first liquid to produce a first solution and then mixing the first solution wi... | 04/08/2008 |
| 7314624 | Nanoemulsion vaccines The present invention provides methods and compositions for the stimulation of immune responses. Specifically, the present invention provides methods and compositions for the use of nanoemulsion compounds as mucosal adjuvants to induce immunity against environmental... | 01/01/2008 |
| 7314746 | Apparatus and method for preparative scale purification of nucleic acids Apparatus and methods are described for pharmaceutical grade manufacture extrachromosomal nucleic acids from cell lysates using flotation to separate and eliminate undesired insoluble cellular debris including chromosomal DNA from the lysates. A gas is introduced to... | 01/01/2008 |
| 7229974 | G cap-stabilized oligonucleotides Oligonucleotides of the formula 5′-(CAP)-(Oligo)-(CAP)-3′ are disclosed where (oligo) is a nucleotide sequence of from 10 to 40 nucleotides in length, and CAP is Gm, where m is an integer of from zero to ten, the two CAP's which ar... | 06/12/2007 |
| 7223585 | Viral purification methods The present invention is directed to an improved method of purifying virus, particularly reovirus. Infectious virus can be extracted from a cell culture with a detergent to produce high titers of virus, and the virus can then be purified by simple steps such as filt... | 05/29/2007 |
| 7223410 | Inactivated respiratory syncytial viral vaccines An immunogenic composition capable of producing a respiratory syncytial (RS) virus specific immune response in a host immunized therewith comprises purified, inactivated RS virus which is substantially free from cellular and serum components and which is non-infecti... | 05/29/2007 |
| 7220747 | Method for preventing damage to or rejuvenating a cellular blood component using mitochondrial enhancer This invention provides methods for treating cellular blood components and other cells containing mitochondria to improve vital qualities of the cells by contacting the cells with a mitochondrial enhancer to the cells. Mitochondrial enhancers prevent damage to and r... | 05/22/2007 |
| RE39494 | Inactivated mycoplasma hyopneumoniae and uses therefor The invention relates to a method for making an inactivated vaccine of Mycoplasma hyopneumoniae by inactivating the bacteria with Thimerosal. The resulting bacterin is mixed with an adjuvant of aluminum hydroxide and DEAE dextran and injected into pigs. The r... | 02/27/2007 |
| 7166745 | Transfection reagents Disclosed are compounds capable of facilitating transport of biologically active agents or substances into cells having the general structure: wherein Q is selected from the gro... | 01/23/2007 |
| 7129223 | Inhibition of SARS-associated coronavirus (SCoV) infection and replication by RNA interference The present invention relates to therapeutic agents useful for the treatment of Severe Acute Respiratory Syndrome (SARS) in humans. In particular, the present invention relates to RNA interference (RNAi) molecules useful for inhibiting the infection and replication ... | 10/31/2006 |
| 7119184 | Oligonucleotides having A-DNA form and B-DNA form conformational geometry Modified oligonucleotides containing both A-form conformation geometry and B-from conformation geometry nucleotides are disclosed. The B-form geometry allows the oligonucleotide to serve as substrates for RNase H when bound to a target nucleic acid strand. The A-for... | 10/10/2006 |
| 7094378 | Method and apparatus for inactivation of biological contaminants using photosensitizers Methods and apparatuses for treating fluids to inactivate microorganisms which may be present therein, said fluid containing one or more components selected from the group consisting of protein, blood and blood constituents are provided. The methods comprise adjusti... | 08/22/2006 |
| 7060103 | Tissue repair fabric A prosthesis, which, when implanted into a mammalian patient, serves as a functioning replacement for a body part, or tissue structure, and will undergo controlled biodegradation occurring concomitantly with bioremodeling by the patients living cells. The prosthesis... | 06/13/2006 |
| 7056507 | Adsorbent for eliminating hepatitis C virus, adsorber, and adsorption method An adsorbent for removing hepatitis C virus which has the ability to adsorb HCV particles, particularly immune-complex HCV particles, from a patient's body blood safely and with high efficiency and high selectivity for enhancing the efficacy of interferon therapy, a... | 06/06/2006 |
| 7049110 | Inactivation of West Nile virus and malaria using photosensitizers Methods and apparatuses are provided for inactivation of microorganisms in fluids or on surfaces. Preferably the fluids contain blood or blood products and comprise biologically active proteins. Preferred methods include the steps of adding an effective, non-toxic a... | 05/23/2006 |
| 7048930 | Expression of core-glycosylated HCV envelope proteins in yeast The present invention relates to the general field of recombinant protein expression, purification of recombinant proteins, diagnosis of HCV infection, prophylactic treatment against HCV infection and to the prognosing/monitoring of the clinical efficiency of treatm... | 05/23/2006 |
| 7037642 | Removing compounds from blood products with porous particles immobilized in a matrix Methods and devices are provided for reducing the concentration of low molecular weight compounds in a biological composition containing cells while substantially maintaining a desired biological activity of the biological composition. The device comprises highly po... | 05/02/2006 |
| 7033813 | Inactivated vaccines for aids and other infectious diseases Presented herein is a description for the manufacturing of inactivated HIV for use in vaccines against AIDS, as well as other inactivated viruses for other infectious diseases. This invention incorporates methods for inactivating infectious virus particles while ret... | 04/25/2006 |
| 7029707 | Method of producing a processed kava product having an altered kavalactone distribution and processed kava products produced using the same A method of producing a processed kava product involves using an extraction solvent, such as liquid CO2, to preferentially extract different kavalactones from the source material at different rates. By controlling the extraction parameters and stopping th... | 04/18/2006 |
| 7026154 | Method of inactivating enveloped viruses in a viral preparation of non-enveloped viruses The present invention relates to a method of inactivating enveloped viruses in a viral preparation predominantly containing non-enveloped viruses by the action of a solvent at a temperature of between −5° C. and +50° C. and at a pH of between about 5 and 9. Its ... | 04/11/2006 |
| 7025916 | Process of making bioengineered collagen fibrils The invention is directed to a class of fiber or strand suspension compositions that may be processed further into viscoelastic pastes or porous solids. The preferred compositions of the invention comprise biologically derived or biologically compatible materials, s... | 04/11/2006 |
| 7022843 | β,β′-dihydroxy meso-substituted chlorins, isobacteriochlorins, and bacteriochlorins Improved β,β′-dihydroxy meso-substituted chlorin, bacteriochlorin or isobacteriochlorin compounds are provided as photosensitizers. Pharmaceutical compositions and photodynamic therapy comprising them are also disclosed. ... | 04/04/2006 |
| 7008784 | Non-infectious, non-replicating, immunogenic human immunodeficiency virus-like particles The present invention is directed toward methods for the production of non-infectious, replication-deficient, immunogenic human immunodeficiency virus (HIV)-like particles. These particles are prepared from a recombinant expression vector comprising a heterologous p... | 03/07/2006 |
| 6994959 | G-rich oligo aptamers and methods of modulating an immune response Aptamer oligonucleotides specifically bind to the DNA binding site of proteins such as Sp1 and Sp1-related proteins which regulate the genes which encode costimulatory molecules such as CD28 and cytokines such as IL-2 and GMCSF. The oligonucleotides compete with the... | 02/07/2006 |
| 6991899 | Cells for detection of influenza and parainfluenza viruses The invention provides cell lines which are useful for the rapid detection and production of influenza and parainfluenza viruses. In particular, the invention relates to transgenic mink lung cells which show increased sensitivity to infection by influenza A, influen... | 01/31/2006 |
| 6989263 | Method for identifying and using compounds that inactivate HIV-1 and other retroviruses by attacking highly conserved zinc fingers in the viral nucleocapsid protein The present invention provides several classes of compounds which can be used to inactivate retroviruses, such as HIV-1, by attacking the CCHC zinc fingers of the viral nucleocapsid protein and ejecting the zinc therefrom. In addition, kits for identifying compounds... | 01/24/2006 |
| 6969523 | Collagen/glycosaminoglycan matrix stable to sterilizing by electron beam radiation Compositions of cross-linked collagen and a glycosaminoglycan are provided which retain characteristics rendering them useful as tissue engineering matrices or scaffolds following terminal sterilization. Also provided are methods for producing these compositions and... | 11/29/2005 |
| 6967239 | Method of filtering viruses from a factor VIII solution Method for preparing a factor VIII solution that is essentially free of viruses and essentially devoid of vWF (von Willebrand factor) and factor VIII-vWF complexes by (a) obtaining a starting factor VIII solution devoid of factor VIII-vWF complexes; and (b) filterin... | 11/22/2005 |
| 6951713 | Absorbing pathogen-inactivating compounds with porous particles immobilized in a matrix Methods and devices are provided for reducing the concentration of low molecular weight compounds in a biological composition, while substantially maintaining a desired biological activity of the biological composition. The device comprises highly porous adsorbent p... | 10/04/2005 |
| 6946136 | Temperature-sensitive and cold-adapted human parainfluenza virus type 2 (HPIV-2) and vaccines based on such virus The present invention relates to isolated, attenuated viral strains of human parainfluenza virus 2 (HPIV-2), which are useful in live vaccine preparations. These strains exhibit a temperature sensitive and cold adapted phenotype useful for stimulating a protective i... | 09/20/2005 |
| 6893856 | Process for preparing virus-inactivated factors 1X and X by membrane chromatography Disclosed is a process for preparing agents containing virus-inactivated vitamin K-dependent plasma components as well as protein C, protein S, factors II, VII, IX and/or X as well as combinations thereof, such as, for example, PPSB preparations, wherein a source co... | 05/17/2005 |
| 6838080 | Induction of immunoglobulin class switching by inactivated viral vaccine The present disclosure provides methods and compositions for inducing an immune response to an antigen, especially in an immunogenic composition comprising sialic acid where the antigen comprises sialic acid and wherein the immunogenic composition further comprises ... | 01/04/2005 |
| 6825027 | Method of production of purified hepatitis a virus particles and vaccine preparation The present invention provides methods of purification of Hepatitis A Virus from the supernatant of an infected cell culture and production of a preparation of purified HAV antigen. The present invention is also directed to an HAV vaccine composition comprising a pr... | 11/30/2004 |
| 6808916 | Method of extracting virus from cell culture The present invention is directed to a method of extracting virus, particularly reovirus, from a culture of cells. Infectious virus can be extracted from the culture with a detergent at a convenient temperature such as 25° C. or 37° C. to produce high virus titers... | 10/26/2004 |
| 6805870 | Paramunity inducer based on combinations of poxvirus components, process to prepare it and its use as medicament Multipotent paramunity inducers are described which are based on combinations of poxvirus components derived from various poxviruses with paramunizing properties and which have been improved in terms of their potency and their paramunization-related activities as co... | 10/19/2004 |
| 6803041 | Equine herpesvirus vaccine A vaccine for protecting a horse against diseases associated with EHV-1 and/or EHV-4 is provided. The vaccine commonly includes inactivated EHV-1 (e.g., chemically inactivated EHV-1 KyA virus) and an adjuvant. The adjuvant can include a cross-linked olefinically uns... | 10/12/2004 |
| 6800432 | Apparatus and method for inactivating viral contaminants in body fluids A method and apparatus for inactivating viruses in a body fluid. A mixture including a therapeutically effective amount of methylene blue and an amount of a body fluid is formed in a container under sterile conditions and then the container is irradiated with a ligh... | 10/05/2004 |
| 6720136 | Solid phase quenching systems Methods of inactivating contaminants of a biological matrix are disclosed. The methods include the steps of: (a) contacting a biological matrix with an inactivating agent including an aziridino moiety, where a portion of the agent reacts with and inactivates the con... | 04/13/2004 |
